Loading...
•
Jun 30, 2022
Agios Q2 2022 Earnings Report
Agios reported business highlights and financial results, generating $3.1 million in U.S. net revenue for PYRUKYND sales.
Key Takeaways
Agios Pharmaceuticals reported Q2 2022 financial results, including $3.1 million in U.S. net revenue from PYRUKYND sales and $2.5 million from licensing intellectual property. The company had $1.1 billion in cash, cash equivalents, and marketable securities as of June 30, 2022.
Generated $3.1 million in U.S. net revenue from PYRUKYND® sales, the first full quarter following FDA approval.
Initiated Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies of PYRUKYND® in pediatric patients with PK deficiency.
Brian Goff to become Chief Executive Officer at Agios on August 8, 2022.
Evolved Agios’ research approach to focus on advancing existing preclinical programs and in-licensing or acquiring well-characterized, high-potential assets.
Forward Guidance
Agios expects to execute on key milestones and priorities in 2022.
Positive Outlook
- Receive European Medicines Agency (EMA) regulatory decision for PYRUKYND® in adults with PK deficiency by year-end.
- Enroll a meaningful portion of patients in the Phase 3 ENERGIZE and ENERGIZE-T studies of PYRUKYND® in not regularly transfused and regularly transfused adults with thalassemia, respectively, by year-end.
- Complete enrollment in the Phase 2 portion of the RISE UP study of PYRUKYND® in sickle cell disease by year-end.
- Initiate Phase 2a study of AG-946 in adults with low- to intermediate-risk MDS by year-end.
- Continue to publish clinical and translational data supporting the utility of PK activators across key disease areas and elucidating the burden of disease for PK deficiency, thalassemia and sickle cell disease.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...